Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Core Insights - Kiniksa Pharmaceuticals reported a net product revenue of $416.4 million for ARCALYST in 2024, reflecting approximately 79% year-over-year growth [1][2] - The company anticipates ARCALYST net product revenue for 2025 to be between $560 million and $580 million [1][6] - Kiniksa expects to maintain a positive cash flow on an annual basis [1][6] Commercial Performance - As of the end of 2024, around 13% of the target population for recurrent pericarditis was on ARCALYST therapy, contributing to the revenue growth [2][6] - The average duration of ARCALYST therapy for recurrent pericarditis patients was approximately 27 months [6] Corporate Update - Kiniksa's leadership will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [4] - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible within 48 hours post-event [4] Company Overview - Kiniksa is focused on developing and commercializing therapeutic medicines for patients with significant unmet medical needs, particularly in cardiovascular and autoimmune diseases [5] - The company’s immune-modulating assets are based on validated mechanisms and aim to address underserved conditions [5]